Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

8 mins ago CAR-T

At which stage of treatment is the best time to choose CAR-T therapy?

CAR-T therapy is often used as a last resort, but it should be introduced earlier for better outcomes. Early use, even as a frontline or 1.5-line treatment, could dramatically increase patient cure rates.

Tumor cells are highly adaptable and intelligent, learning to evade treatments over time. Treating tumors early, before they become stronger, is crucial.

CAR-T should not be considered a “last resort” in treatment, as waiting too long may reduce its effectiveness. It’s better to “kill the tumor when it’s young” before it becomes more resilient and difficult to eliminate.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#cart #carttherapy #CAR_T #leukemia #lymphoma #cancer #tumor #bloodcancer

2 hours ago CAR-T

Russian Patient Successfully Cured of Follicular Lymphoma(FL) with CAR-T Therapy in China!

可能是包含下列内容的图片：医院和文字

#FL #Lymphoma #FollicularLymphoma #CARTTherapy #CART #Patientstory

Patient Story – Oleg’s Cancer Journey:

Today, we share the story of a 46-year-old patient from Russia named Oleg. Oleg was diagnosed with follicular lymphoma and, after multiple rounds of chemotherapy, achieved complete remission. Unfortunately, the disease relapsed, with several enlarged lymph nodes appearing in his abdomen and other areas. Faced with this resurgence, Oleg was determined not to give up and decided to seek new treatment options to improve his quality of life.

Tailor-Made CAR-T Treatment Plan:

After extensive research, Oleg contacted us and connected with lymphoma experts from our Advanced Medicine in China team. Through video consultations and detailed discussions, he decided to pursue CAR-T cell therapy. With confidence in the potential of Chinese CAR-T therapy, Oleg and his family traveled thousands of miles to China to begin his CAR-T treatment journey.

Given Oleg’s high tumor burden and relapse after chemotherapy, the Chinese medical team customized a bridging therapy for him, combining targeted drugs with low-dose radiotherapy to reduce the tumor burden and improve the immune environment. Special care was taken when designing the radiotherapy plan, as Oleg still had fertility concerns. The team created a personalized treatment plan that balanced safety and effectiveness. During the treatment process, Oleg experienced almost no significant side effects, demonstrating excellent treatment compliance and tolerance. He maintained a strong relationship of trust and communication with the medical team.

Complete CR – A New Life After Treatment

Oleg’s CAR-T cell infusion process went smoothly. Despite a history of migraines, he only experienced mild headaches and low-grade fever after the treatment. Under the meticulous care of the treatment team, the CAR-T cells demonstrated strong anti-tumor effects, with minimal side effects. For a patient with a high tumor burden, he only developed grade 1 cytokine release syndrome (CRS), and his blood counts began to recover about a week after the infusion. Overall, he remained in good condition.

Fifteen days after the CAR-T infusion, an abdominal ultrasound showed significant shrinkage of the enlarged lymph nodes. Three months later, a PET-CT scan brought even more surprising news—Oleg’s tumors had completely disappeared, and his response was evaluated as a complete remission (CR). This meant that Oleg had beaten cancer!

Today, Oleg is doing better and better, running daily. He is especially grateful for the support and care provided by the Advanced Medicine in China team and the Chinese experts. Despite being far from home, he never felt inconvenienced during his treatment in China. The doctors and nurses not only communicated with him patiently but also provided significant help in his daily life.

Why Choose CAR-T Treatment in China?

CAR-T therapy has shown remarkable efficacy in treating relapsed and refractory follicular lymphoma, with clinical data showing an objective response rate (ORR) of over 90% and a median duration of response exceeding three years! Oleg’s case is a testament to China’s advanced medical technology. Traditional chemotherapy tends to lose effectiveness after repeated treatments, while CAR-T therapy offers the possibility of curing diseases like follicular lymphoma, which were previously considered incurable.

For patients like Oleg, who seek a high-quality life, China’s CAR-T therapy is bringing new hope.

World-Class – China’s CAR-T Indications and Beyond

Today, China’s CAR-T is not only actively involved in global research but is also leading many developments in the CAR-T field. For patients like Oleg with follicular lymphoma, only China and the U.S. have approved CAR-T products targeting this condition. However, China’s CR rate is notably higher.

Currently, China offers the most extensive range of CAR-T indications, including relapsed or refractory diffuse large B-cell lymphoma (DLBCL) for first-line, second-line, or third-line treatment failures or relapse; relapsed follicular lymphoma (FL) after second-line treatment; mantle cell lymphoma (MCL) with multiple treatment failures; unspecified DLBCL; large B-cell lymphoma transformed from FL; primary mediastinal large B-cell lymphoma; and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CART #CancerTreatment #AdvancedMedicineInChina #Lymphoma #FollicularLymphoma #CancerRemission #MedicalTourism #ChinaCare #HealingJourney #CancerFree #Immunotherapy #GlobalHealthcare

3 hours ago Solid tumor , CAR-T

Revolutionizing Cancer Treatment: China’s Groundbreaking CAR-T Therapy Targets Glioblastoma

#CAR_Therapy #Glioblastoma #CancerResearch #InnovativeMedicine

A Chinese medical team has recently made significant progress in t

he field of CAR-T cell therapy, bringing new hope for the treatment of solid tumors such as glioblastoma (GBM). While CAR-T therapy has achieved great success in treating hematologic

al malignancies, its efficacy against solid tumors like glioblastoma remains limited. The innovative research by the Chinese medical team has greatly enhanced the attacking capability of CAR-T cells against solid tumors through the design of high-affinity protein binders from scratch.

The study, published in Nature Biomedical Engineering under the title “Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders,” presents a novel Binder CAR strategy that replaces the traditional scFv antibody structure. Through computational design, the Chinese research team precisely constructed a new protein binding domain targeting highly expressed antigens in glioblastoma—EGFR and CD276. This new Binder CAR demonstrated significant anti-tumor effects in experiments compared to traditional scFv CAR, especially in the treatment of glioblastoma, a highly malignant tumor. The Binder CAR not only enhanced tumor-killing capacity but also effectively prolonged the survival time of experimental mice.

This groundbreaking technology showcases China’s strong innovative capability in cancer treatment. The Binder CAR can not only identify tumor antigens more stably and efficiently but also reduces the potential T cell exhaustion issues associated with traditional CAR-T therapy, significantly improving treatment durability. In the future, this strategy is expected to be applied to the treatment of other solid tumors, heralding a new era for CAR-T therapy.

China is not only pioneering the era of CAR-T in solid tumors but has also achieved remarkable success in hematological malignancies. Whether it’s the CD19 CAR-T therapy for relapsed or refractory large B-cell lymphoma (DLBCL) and leukemia that is already on the market, or the BCMA CAR-T therapy for multiple myeloma, China has made substantial progress and is now at the forefront of global CAR-T advancements. Additionally, the number of CAR-T therapies in clinical development is astounding, including dual-target CAR-T therapies targeting CD20, CD22, and CD30, or the recently headline-grabbing universal CAR-T therapies, as well as the explosive news regarding CAR-T therapies for autoimmune diseases. China is in a position of complete leadership. We look forward to bringing more good news to cancer patients worldwide.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CART #CancerTreatment #Glioblastoma #ChinaInnovation #MedicalBreakthrough #SolidTumors #Immunotherapy #CureCancer #Biotech #MedicalResearch

5 days ago patient story

The Russian Dancer’s CAR-T Treatment Journey in China: Rekindling Hope for Life

Journey in China

#MiraclesOfLife #ChinaCART #CancerTreatment #CancerWarrior #TumorTherapy #patientstory #lymphoma

CAR-T cell therapy is a groundbreaking cancer treatment that harnesses the patient’s own immune system by engineering T cells to recognize and attack cancer cells. In recent years, this therapy has brought new hope to patients with refractory hematologic cancers worldwide. China, with its advanced medical technology and extensive clinical experience, has become one of the leading countries globally for CAR-T therapy.

#### Patient Story

Ana is a vibrant dance coach from Russia. She loves life, en

joys a happy marriage, has two adorable cats, and her students, whom she affectionately calls her “kids.” However, fate cruelly altered her life when she was diagnosed with B-cell lymphoblastic lymphoma (B-LBL).

During her long battle after the diagnosis, Ana underwent chemotherapy, localized radiation therapy, and even traveled to Europe for an allogeneic hematopoietic stem cell transplant. Despite her resilience, the shadow of relapse followed her closely, as conventional chemotherapy and other treatments failed to yield lasting results, and the cancer returned.

#### CAR-T Therapy for B-LBL in China

When hope seemed to fade, Ana decided to try a cutting-edge treatment—CAR-T cell therapy. This innovative therapy has shown remarkable efficacy in treating relapsed and refractory hematologic cancers worldwide. With a strong will to live, Ana sought consultation with experts from the Advanced Medicine in China team and was transferred to a hospital in China, hoping for a new chance at life. In China, after comprehensive examinations, the medical team found that the tumor had spread to her limb bones and bone marrow, proliferating at an alarming rate. Faced with such a high tumor burden, the team decided to administer CD19-targeted CAR-T cell therapy and took steps to reduce the tumor load beforehand to improve the chances of success.

A miracle occurred within just two weeks of treatment. On the 14th day, a bone marrow biopsy revealed that Ana’s tumor cells had disappeared, and the treatment had shown significant results. Even more encouraging was the fact that her pain symptoms had completely vanished, and her overall condition gradually improved. While full recovery will take time to observe, Ana’s condition has stabilized as expected.

#### Remission and Future

Now, Ana is in the recovery phase, and her treatment in China has made tremendous progress. Future monitoring and care will continue remotely with the Chinese medical team. This treatment journey not only reignited hope in Ana’s life but also serves as an inspiration to many others battling the disease: CAR-T cell therapy might be a beacon of light in the fight against hematologic cancers.

Ana’s story is a vivid example of CAR-T therapy in China, highlighting the country’s leading role in the global fight against cancer. We hope this innovative therapy can offer new chances of life to many more patients like Ana.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

5 days ago Lymphoma

Chinese Medical Team’s Fourth-Generation CAR-T Therapy: Revealing New Hope for B-Cell Lymphoma Treatment

Lymphoma

#CART #CellDiscovery #Lymphoma #BCellLymphoma #RRLBCL #IL7 #CCL19

In recent years, China has made significant progress in medical innovation, especially in the field of Chimeric Antigen Receptor T-cell (CAR-T) therapy, dramatically changing the landscape of treatment for malignant blood cancers. Recently, a team of medical professors from Zhejiang, China, released the results of a clinical trial demonstrating the breakthrough effectiveness of fourth-generation anti-CD19 CAR-T cell therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The study, published in the renowned journal Cell Discovery (“Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma”), sheds light on this innovative approach.

New Highlights of CAR-T Therapy

Traditional anti-CD19 CAR-T cell therapy has already shown excellent efficacy in treating blood cancers like R/R LBCL, but tumor relapse remains a significant challenge. To address this, Chinese researchers have developed a new fourth-generation CAR-T cell therapy that co-expresses two cytokines, IL-7 and CCL19. These cytokines enhance the activity of immune cells, improving CAR-T cells’ anti-tumor effects and extending patient survival.

Efficacy and Potential

The Chinese medical team included 39 patients, aged 29 to 73, in this study. They received a single infusion of the fourth-generation anti-CD19 CAR-T cells co-expressing IL-7/CCL19. The results showed that within three months of treatment, the overall response rate (ORR) reached 79.5%, with a complete response rate (CR) of 56.4%. This therapy also demonstrated a notable long-lasting effect, with a median progression-free survival (PFS) of 13 months, and an estimated two-year overall survival rate (OS) of 53.8%.

The study found that the expansion of CAR-T cells in the blood and plasma levels of IL-7/CCL19 were closely associated with clinical outcomes. Higher CAR-T cell expansion and peak concentrations of IL-7/CCL19 were linked to better overall survival (OS), further confirming that this combination can enhance CAR-T cells’ anti-tumor potential.

Why Is This Study So Important?

The introduction of this new CAR-T therapy in China marks a significant leap forward in cancer treatment. It not only induces long-lasting remission but also significantly extends patient survival, with manageable safety, offering new hope to patients facing resistant blood cancers. China’s rapid advancements in CAR-T technology showcase its growing influence in the global biotechnology sector.

This groundbreaking research not only solidifies China’s important position in medical innovation but also lays the foundation for future development and application of more CAR-T therapies, potentially bringing revolutionary changes to cancer treatment worldwide.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CAR_Therapy #CancerTreatment #MedicalInnovation #BCellLymphoma #ChinaBiotech #Immunotherapy #FourthGenerationCAR_T #BloodCancer #CytokineTherapy #OncologyBreakthrough #CellDiscovery #CancerResearch #TumorImmunology #PatientSurvival #Hematology

5 days ago CAR-T

Global CAR-T Products on the Market and BCMA-Targeted CAR-T Products

Global CAR-T Products on the Market

CAR-T

#CART #DLBCL #ALL #FL #MCL #MM #LBCL #Leukemia #Lymphoma #MultipleMyeloma

Globally Approved BCMA-Targeted CAR-T Products

– Multiple Myeloma

#CART #MM #RRMM #MultipleMyeloma #Myeloma

Multiple Myeloma

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

7 days ago Leukemia

A CAR-T Success Story in China: A Beacon of Hope for Acute Myeloid Leukemia(AML) Patients

patient story

#CAR-T #AcuteMyeloidLeukemia #AML #ChinaHealthcare #patientstory #CD33

In the field of cancer treatment, China’s medical advancements have brought new therapeutic opportunities for patients, especially with CAR-T cell therapy. Although CAR-T has achieved significant success in treating lymphoid tumors, its application in myeloid malignancies, particularly acute myeloid leukemia (AML), has been challenging. However, a recent successful case of CD33 CAR-T therapy in China has ignited hope for patients with refractory relapsed AML.

#### Patient Story

The patient is a 25-year-old Chinese male who initially sought medical attention due to dizziness and fatigue. He was eventually diagnosed with high-risk AML associated with the DEK::CAN fusion gene, which has a very poor prognosis. Despite some initial effectiveness of chemotherapy and undergoing allogeneic hematopoietic stem cell transplantation (Allo-HSCT), the disease relapsed six months later.

After multiple attempts with targeted therapies and donor cell infusions, the results remained unsatisfactory. Just when traditional treatments seemed ineffective and hope was dwindling, the patient sought out my Advanced Medicine in China team.

#### Breakthrough Treatment: China’s CD33 CAR-T

The patient received a consultation and treatment from the medical experts of my Advanced Medicine in China team. After admission and initial preparations, he underwent CD33 CAR-T therapy, an innovative treatment specifically targeting myeloid tumors. After three days of chemotherapy conditioning, the CAR-T cells were infused on day 11. Although there was a mild fever during this period, the patient experienced no significant discomfort. Subsequently, the bone marrow examination revealed astonishing news: leukemia cells had completely disappeared, and the DEK::CAN fusion gene was nearly undetectable, indicating that the disease was in a state of complete remission.

Despite experiencing a lung infection during treatment, the patient’s condition improved after antibiotic therapy. He did not suffer from severe side effects such as persistent cytopenia, and his blood parameters returned to normal. He was ultimately discharged smoothly.

#### Sustained Remission and a Bright Future

Two months after receiving CD33 CAR-T cell therapy, the patient remains in a state of complete molecular remission, with normal blood counts and a significant improvement in quality of life. This case demonstrates that CAR-T therapy not only successfully controlled refractory relapsed AML but also significantly enhanced the patient’s chances of survival and quality of life.

#### A New Chapter for CAR-T Treatment of AML in China

This case highlights China’s innovative capabilities in the field of CAR-T therapy, particularly in the treatment of myeloid malignancies. For AML patients like this young man who have faced multiple treatment failures, China’s CAR-T therapy undoubtedly brings new hope.

Although global CAR-T therapies for myeloid malignancies are still in their infancy, this groundbreaking advancement in China indicates that CAR-T therapy is poised to become a crucial method for treating refractory relapsed AML in the future. As research deepens and technologies mature, this therapy may save more patients in dire circumstances.

China’s leading position in CAR-T treatment is bringing new hope to patients worldwide. For all AML patients, this story proves that the path to a brighter future has been paved, and for many, it begins with China’s CAR-T therapy.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CancerTreatment #InnovativeTherapy #PatientSuccess #MedicalAdvancements #HopeInHealthcare #Immunotherapy

7 days ago Myeloma

Chinese Medical Team Releases Dual-Target CAR-T Data: 100% Complete Remission Rate in High-Risk MM Patients

High-Risk MM

#CARTTherapy #MultipleMyeloma #BCMA #CD19 #JAMAOncology #MM #HRMM #DualTarget

Once again, a Chinese medical team is at the forefront of innovation, making significant strides in the field of CAR-T cell therapy. A recent study published in JAMA Oncology (B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma) revealed remarkable results for the dual-target BCMA/CD19 CAR-T therapy in high-risk newly diagnosed multiple myeloma (NDMM) patients. In this study, all 19 participants achieved stringent complete remission (sCR) and were found to be minimal residual disease (MRD) negative, resulting in an astounding 100% remission rate.

CAR-T Therapy: A Breakthrough in Hematologic Cancer Treatment

Multiple myeloma (MM) is a challenging hematologic cancer, particularly for patients with high-risk features, where traditional treatments often show limited efficacy. CAR-T cell therapy is an innovative immunotherapy that reprograms a patient’s own T cells to recognize and attack cancer cells. In recent years, this therapy has shown significant success in treating leukemia, lymphoma, and relapsed/refractory MM (RRMM). The latest study further demonstrates that dual-target CAR-T therapy, focusing on BCMA and CD19, can significantly improve the prognosis for high-risk MM patients.

The Impressive Results of China’s Dual-Target CAR-T Therapy

The CAR-T therapy used in this study, GC012F, targets both B-cell maturation antigen (BCMA) and CD19 surface antigens, showing powerful anti-tumor effects. Every patient in the study not only achieved complete remission after treatment but also maintained a long-term MRD-negative status, meaning that traces of cancer cells were nearly undetectable post-therapy.

More importantly, the study highlighted the swift effectiveness of the Chinese GC012F therapy—patients reached their first complete remission in a median time of just 84 days, with MRD-negative status achieved in as little as 28 days. This rapid anti-tumor response provides a crucial treatment window for patients, significantly improving their prognosis.

Safety and Future Prospects

In addition to its impressive efficacy, GC012F demonstrated favorable safety. Only 27% of patients experienced mild to moderate cytokine release syndrome (CRS), and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. This is in stark contrast to previous studies in relapsed/refractory patients, where CRS rates were higher, highlighting the safety advantage of this therapy in newly diagnosed patients.

Though the study sample size was small, these findings bring new hope for high-risk multiple myeloma patients. As larger clinical trials are conducted and combination therapies are explored, this therapy has the potential to offer better survival outcomes for more patients.

Conclusion

China’s CAR-T cell therapy research continues to lead the way in hematologic cancer treatment. The success of the BCMA/CD19 dual-target CAR-T therapy not only demonstrates its strong efficacy in high-risk multiple myeloma but also provides a new direction for treating hematologic cancers globally. As research deepens, we anticipate that this groundbreaking therapy will bring new life-saving opportunities to more patients.

This breakthrough in Chinese CAR-T therapy represents not only scientific progress but also underscores China’s pivotal role in the global fight against cancer.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CancerTreatment #Immunotherapy #MedicalInnovation #CancerResearch #ChinaHealthcare #HematologicCancer #CancerBreakthrough

1 week ago patient story

The Miracle of CAR-T Therapy in China: Mrs. Li’s Battle Against Lymphoma

patient story

In the long journey of life, cancer often strikes like a sudden storm, leaving patients and their families devastated. Mrs. Li, a young and resilient mother from China, was no exception. Two years ago, she was diagnosed with relapsed and refractory B-cell non-Hodgkin lymphoma. The shocking news felt like a bolt from the blue, throwing her once-happy family into the depths of despair.

Traditional chemotherapy and radiation therapy once brought a flicker of hope for Mrs. Li, temporarily alleviating her condition. However, fate seemed to play a cruel trick on her again, as the tumor returned with more aggression, no longer responding to conventional treatments. The repeated rounds of therapy took a toll on her body and spirit. Both Mrs. Li and her family were pushed to the brink of collapse, feeling trapped in a deep abyss with no light of hope in sight.

Just when Mrs. Li was about to give up, fate intervened. Thanks to the relentless efforts of the “Advanced Medicine in China” team, they successfully connected Mrs. Li with the country’s top hematology specialists. After a series of communications and coordination, this expert became her last lifeline, taking on the responsibility of devising the best treatment plan during her darkest hours.

After conducting a comprehensive and detailed examination of Mrs. Li, the expert, relying on extensive experience and professional judgment, decisively recommended CAR-T therapy, a cutting-edge treatment. This innovative immunotherapy acts like a magical key, reactivating the patient’s immune system to precisely target and attack cancer cells, offering a new glimmer of life. Faced with this final hope, Mrs. Li carefully considered her options and bravely decided to seize it, determined to fight once more for her life.

The results were truly remarkable. CAR-T therapy produced astonishing effects in Mrs. Li, like a dazzling light in the darkness. After just a few weeks, follow-up tests showed that her tumor had significantly shrunk, and the symptoms that had once plagued her improved dramatically. This was a pivotal moment, allowing Mrs. Li and her family to rediscover hope for the future.

In the months that followed, under close monitoring and consolidation treatment, Mrs. Li’s condition stabilized, as though the ferocious beast of cancer had been tamed. Ultimately, she achieved a miracle—her cancer reached complete remission. For Mrs. Li and her family, this was nothing short of extraordinary, filling their hearts with overwhelming joy and gratitude. They were not only rekindled with the flame of hope for life but also deeply thankful to the “Advanced Medicine in China” team and CAR-T therapy.

As the recommending team, “Advanced Medicine in China” feels honored to have witnessed Mrs. Li’s recovery journey. This is not just a victory for one patient but a successful step forward in the ongoing battle against cancer, inspiring the team to continue seeking rays of hope for more patients. Mrs. Li’s story has become a powerful tale of triumph, spreading rapidly among fellow patients. Her courage and perseverance have set an example for many others bravely fighting blood cancer, encouraging them to press on and never give up.

Through Mrs. Li’s case, CAR-T therapy in China has once again demonstrated its immense potential in the treatment of lymphoma. Like a rising star, it is bringing new hope to blood cancer patients worldwide, illuminating their path toward overcoming the disease. In the future, CAR-T therapy in China will undoubtedly create more miracles, offering patients the dawn of life and a brighter future.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#patientstory #CARTTherapy #CancerSurvivor #Lymphoma #LymphomaTreatment #BloodCancerAwareness#MedicalMiracles #ChinasMedicalAdvances #CancerResearch #PatientStories #HopeAgainstCancer #Immunotherapy #FightCancer #CancerRemission #CourageToFight #BreakthroughInMedicine

1 week ago Leukemia

Nature Medicine | New Breakthrough in China’s CAR-T Therapy: Significant Progress in Allogeneic CD5 CAR-T Treatment for Relapsed T-ALL

T-ALL

#CAR-TTherapy #TALL #ALL #Leukemia #RelapsedLeukemia #TCellLeukemia #CD5 #CD7 #CART

Recently, a collaborative research study conducted by multiple Chinese medical and research institutions was published in Nature Medicine. This study, titled “Allogeneic CD5-specific CAR-T Therapy for Relapsed/Refractory T-ALL: A Phase 1 Trial,” demonstrated the potential of CD5 CAR-T cells in treating relapsed/refractory acute T-cell lymphoblastic leukemia (R/R T-ALL).

### Innovative Therapy Brings Hope

For a long time, patients with relapsed/refractory T-ALL have lacked effective treatment options and faced a poor prognosis. In recent years, CD7 CAR-T cell therapy has shown some efficacy in these patients, but CD7-negative relapse remains a significant challenge. This study focuses on evaluating the safety, efficacy, and pharmacokinetics of CD5 CAR-T cells, offering new insights for future treatments.

The study included 19 patients, most of whom had previously received CD7 CAR-T therapy. Results showed that this therapy was safe, with no dose-limiting toxicity observed, and adverse events were primarily manageable hematologic toxicity. In terms of efficacy, all patients achieved complete remission within 30 days of treatment. The study also demonstrated, for the first time, the persistence of CD5 CAR-T cells in the body and their ability to eliminate CD5+ T cells, indicating strong anti-tumor activity.

### Breakthrough in Treating Relapsed Patients

In addition to safety and efficacy, the research team explored the coexistence of CD7 CAR-T and CD5 CAR-T cells and studied immune cell changes in the patients. For those who relapsed after CD7 CAR-T treatment with CD7-negative cells, CD5 CAR-T offered a new salvage therapy, providing additional treatment options for such patients.

### Multidisciplinary Collaboration Drives Clinical Progress

Unlike CAR-T therapies for B-cell tumors, treating T-cell malignancies poses more challenges, particularly in controlling immune deficiencies. Dr. Jing Pan and her team conducted in-depth research on target selection and relapse mechanisms, while also focusing on balancing treatment safety and efficacy.

This study was made possible by the collaborative efforts of various medical institutions in China, collectively opening up a new therapeutic pathway for T-cell tumor patients.

### Looking Ahead

As innovations and advances in T-ALL treatment continue, the team plans to further research CD5 CAR-T therapy and collaborate with experts across various fields to optimize CAR-T treatment protocols, helping more patients with T-cell lymphoblastic tumors overcome their diseases.

This series of research achievements not only brings new hope to patients with R/R T-ALL but also provides valuable insights for the future development and optimization of CAR-T therapies. The team remains committed to a patient-centered approach, striving to drive continuous breakthroughs and innovations in T-cell tumor treatment.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#Immunotherapy #CancerTreatment #TALLResearch #LeukemiaBreakthrough #Hematology #CellTherapy #CancerInnovation #CancerResearch #ClinicalTrials #MedicalBreakthrough

1 week ago CAR-T

China’s BCMA CAR-T Therapy Offers Last Hope for Relapsed Multiple Myeloma Patients

### China’s BCMA CAR-T Therapy Offers Last Hope for Relapsed Multiple Myeloma Patients

CAR-T Therapy

#MultipleMyeloma #CAR_TTherapy #BCMACART #CART

Multiple myeloma remains a difficult-to-cure disease, and every year, countless patients around the world face this devastating diagnosis. While treatment options have improved in recent years, and patients’ survival times have extended, drug resistance remains a significant challenge. For patients who have experienced multiple relapses and are resistant to various treatments, the future can seem bleak. Fortunately, with the emergence of BCMA CAR-T cell therapy, a new ray of hope is illuminating the path for these patients.

This is the story we’re sharing today, about a 76-year-old female patient who regained control of her life through CAR-T therapy.

#### The First Encounter with the Disease

In 2020, this Chinese 76-year-old woman noticed a decline in appetite and a rapid weight loss, accompanied by persistent rib pain. She had no idea that these symptoms were early signs of multiple myeloma. After several medical tests, her Chinese doctors confirmed the diagnosis: 31% of her bone marrow cells were plasma cells, her M-protein levels reached 85.7 g/L, and calcium levels in her blood were abnormally high. Multiple bones throughout her body also showed signs of significant damage.

The diagnosis left the patient shocked and confused. Multiple myeloma wasn’t her first health challenge; she also had a history of Parkinson’s disease. However, she remained hopeful, believing that with the right treatment, her condition could be controlled. But fate had other plans.

#### The Struggle and Relapse

At the beginning of 2023, the patient’s condition relapsed rapidly. Due to a prolonged lack of regular treatment, her disease worsened, and she became resistant to many standard therapies. After extensive tests, her medical team discovered that she had a high-risk mSMART 3.0 profile, with genetic abnormalities including 1q21 amplification and a t(4;14) translocation, making her prognosis extremely poor. She was now considered a “triple-refractory” patient, resistant to three main treatment categories.

Faced with this complex and challenging situation, the Chinese doctors didn’t give up. After multiple discussions and research, they recommended a cutting-edge therapy — BCMA CAR-T cell therapy. This treatment involves modifying the patient’s immune cells to target and destroy cancer cells. However, to undergo this advanced therapy, the patient first needed to undergo bridging treatment to reduce the tumor burden in her body.

#### Bridging Treatment: A Turning Point

To prepare for CAR-T therapy, the Chinese doctors initially prescribed the DKD regimen, a combination therapy intended to quickly reduce the cancer cell load. However, the first treatment cycle didn’t bring significant improvement, and her free light chain levels remained high. Both the patient and her family felt disappointed, but the Chinese doctors acted quickly, switching to the KAD regimen, which included liposomal doxorubicin to further enhance the treatment’s effectiveness.

This adjustment brought immediate results. After a few weeks, her free light chain levels began to drop, and her condition showed partial remission (PR). This meant she was finally ready for CAR-T cell therapy.

#### The Miracle of CAR-T Therapy

CAR-T therapy is a breakthrough technology where the patient’s immune cells are extracted, genetically modified to recognize and destroy cancer cells, and then reintroduced into the body. These engineered cells act like precision-guided weapons, specifically targeting her cancer cells.

The patient responded positively to the treatment. Within just a few weeks, her condition was significantly controlled, with results showing a very good partial response (VGPR). For such a complex case of relapsed and refractory disease, this was a major success.

#### The Significance of the Story

This patient’s story highlights China’s latest advancements in the treatment of multiple myeloma. The use of carfilzomib-based bridging therapy paved the way for CAR-T therapy, successfully giving a patient with a poor prognosis a new chance at life. For those facing the dual challenges of drug resistance and relapse, BCMA CAR-T therapy offers not just a new treatment option, but a lifeline.

The product that has renewed hope for this 76-year-old Chinese woman is a BCMA-targeted CAR-T therapy that has already been launched in China. China is changing the fate of patients worldwide through advanced cancer treatments. Notably, in the field of CAR-T technology related to hematologic tumors and multiple myeloma, two BCMA CAR-T products have been approved in China. Especially commendable is Reindeer Bio’s independently developed fully human BCMA product, FUCASO, which has achieved an astonishing complete remission (CR) rate of 82.4%, the highest among all globally approved products. An increasing number of foreign multiple myeloma patients are now seeking treatment in China to access better therapies at more affordable prices. As China continues to develop cutting-edge medical therapies, aggressive treatments like CAR-T undoubtedly provide new hope for the future of multiple myeloma treatment.

Follow us for more stories of medical innovation and to witness how miracles of life are born in China!

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#MultipleMyeloma #CancerTreatment #CAR_TTherapy #BCMACAR_T #CancerSurvivor #Immunotherapy #ChinaMedicalInnovation #CancerResearch #CancerHope #MedicalBreakthrough #MyelomaAwareness #AdvancedCancerCare #RelapsedMyeloma #LifeSavingTreatment #PatientSuccessStory #CancerCare #GlobalHealth #CAR_TSuccess #Oncology #CancerSupport

#ChineseMedical #ChinaHealthcare #MedicalCareInChina #HealthcareInChina · #USMedical #USHealthcare #HealthcareInUSA #AmericanMedical #MedicalCareInUSA #USAHealth #AmericanHealthcare

2 weeks ago CAR-T

Why Does China Have a Unique Advantage in the Field of CAR-T Therapy?

CAR-T

#CAR_Therapy #CancerTreatment #MedicalInnovation #ChinaMedical

In recent years, China has made rapid advancements in medical technology, particularly in the area of CAR-T (Chimeric Antigen Receptor T-cell) therapy. This cutting-edge cancer treatment involves reprogramming a patient’s own T cells to recognize and attack cancer cells. This revolutionary therapy has transformed treatment options for various malignancies, with China’s innovations and applications standing out globally.

### 1. Scientific Innovation and Technological Breakthroughs

China has reached a world-leading level in CAR-T research and development. Numerous prestigious medical schools and research institutions in China have actively contributed to this field, leading to the creation of several novel CAR-T treatment methods. Chinese scientists have pioneered significant innovations in CAR-T cell engineering, toxicity control, and target selection. For example, the CD19 CAR-T therapy for hematologic malignancies is widely used in China. Additionally, the fully human BCMA-targeted CAR-T product, Equecabtagene Autoleucel, used for multiple myeloma, has achieved a complete remission (CR) rate of 82.4%. Recently, Nature featured China’s breakthrough in using universal CAR-T for autoimmune diseases. New CAR-T therapies targeting solid tumors are also progressing rapidly.

### 2. Cost-Effectiveness and Extensive Clinical Application

Compared to some Western countries, CAR-T therapy in China is more affordable, partially due to lower production and R&D costs. A surge of local pharmaceutical and biotech companies has emerged, promoting the domestic production of CAR-T products and reducing reliance on imported drugs. This efficient supply chain management has not only lowered treatment costs but also made the personalized therapy more accessible to patients. While CAR-T therapy in the U.S. can cost $700,000–$800,000, the cost in China is about one-fifth to one-seventh of that.

Moreover, the faster approval process for clinical trials in China enables researchers to quickly bring new therapies to market, allowing patients earlier access to innovative treatments. This efficiency is supported by streamlined regulatory frameworks and healthcare reforms.

### 3. Government Policy Support and International Collaboration

The Chinese government has implemented various policies to strongly support biomedical innovation, including the development and application of CAR-T technology. For example, the National Medical Products Administration (NMPA) has accelerated the approval process for CAR-T therapies, simplifying regulatory procedures, and encouraging international cooperation and technology transfer. Many international pharmaceutical giants have partnered with Chinese companies to jointly advance CAR-T therapy research and commercialization. This openness has established China as a key global center for CAR-T treatment.

### 4. Large Patient Population Driving Research and Application

As the most populous country, China has a vast cancer patient population, providing abundant clinical cases and research resources for the application and further optimization of CAR-T therapy. This large patient base allows China to conduct large-scale clinical trials in a short time, accelerating the validation of treatment effectiveness and maturity. In China, not only are there local consensus guidelines for CAR-T usage, but each physician applying CAR-T has significant experience in both initial treatments and post-therapy management.

### 5. Interdisciplinary Collaboration and Development

China’s advancements in cellular immunotherapy are not solely dependent on progress in medical fields but are also supported by the integration of interdisciplinary technologies such as artificial intelligence, gene editing, and materials science. For instance, AI is increasingly playing a role in optimizing and personalizing CAR-T therapy designs. Gene editing tools like CRISPR are also widely applied in China for designing CAR-T cells, making them more precise and effective.

### Conclusion

China’s unique advantages in CAR-T therapy stem from continuous scientific breakthroughs, lower treatment costs, strong government support, and a vast patient base. As technology advances and international collaborations deepen, China is poised to play an increasingly important role in the global fight against cancer. CAR-T therapy offers new hope to cancer patients, and China’s innovation and strength are helping bring this hope to fruition sooner.

This is not just China’s advantage; it is a blessing for cancer patients worldwide.

🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#ChimericAntigenReceptor #CancerResearch #Immunotherapy #ChinaMedicalAdvancements #Biotech #GeneTherapy #CellTherapy #HealthcareRevolution #CancerCare #AIinHealthcare #PrecisionMedicine #GlobalHealth

Menu

Tags Archives: CAR-T